Gilead Sciences, Inc. $GILD Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 926,242 shares of the biopharmaceutical company’s stock after purchasing an additional 91,198 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Gilead Sciences were worth $117,021,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of GILD. Aviva PLC boosted its stake in Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after purchasing an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $1,418,000. NBC Securities Inc. lifted its stake in shares of Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Gilead Sciences by 43.9% in the fourth quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company’s stock worth $6,973,000 after buying an additional 17,325 shares in the last quarter. Finally, Flputnam Investment Management Co. boosted its position in Gilead Sciences by 66.5% during the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock worth $12,978,000 after acquiring an additional 42,243 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares of the company’s stock, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock valued at $6,568,860 over the last quarter. 0.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays cut their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Gilead Sciences Price Performance

Shares of GILD stock opened at $138.14 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a market capitalization of $171.29 billion, a PE ratio of -51.74 and a beta of 0.32. The firm’s 50-day moving average is $129.93 and its two-hundred day moving average is $136.44. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.